Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Testosterone-guided ADT for prostate cancer

Nature Reviews Urology volume 13, pages 189–191 (2016)Cite this article

Subjects

Luteinizing-hormone-releasing hormone (LHRH) agonists as androgen deprivation therapy (ADT) for men with advanced prostate cancer are usually administered indefinitely on a fixed schedule. However, using testosterone level to guide ADT in these patients could lead to reductions in cost and some symptomatic improvements.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Niraula, S. et al. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. Prostate 76, 235–242 (2016).

    Article  CAS  Google Scholar 

  2. Rosner, W. et al. Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 95, 4542–4548 (2010).

    Article  CAS  Google Scholar 

  3. Ishizaki, F. et al. Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci. Rep. 3, 1528 (2013).

    Article  Google Scholar 

  4. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).

    Article  Google Scholar 

  5. Oefelein, M. G., Feng, A., Scolieri, M. J., Ricchiutti, D. & Resnick, M. I. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56, 1021–1024 (2000).

    Article  CAS  Google Scholar 

  6. Morote, J. et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 178, 1290–1295 (2007).

    Article  CAS  Google Scholar 

  7. Klotz, L. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J. Clin. Oncol. 33, 1151–1156 (2015).

    Article  CAS  Google Scholar 

  8. Oefelein, M. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J. Urol. 169, 251–255 (2003).

    Article  CAS  Google Scholar 

  9. Pathak, A. S., Pacificar, J. S., Shapiro, C. E. & Williams, S. G. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J. Urol. 177, 2132–2135 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tsutomu Nishiyama and Tatsuhiko Hoshii are at the Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Urasa 4132, Minamiuonumashi, Niigata 949–7302, Japan.,

    Tsutomu Nishiyama & Tatsuhiko Hoshii

Authors
  1. Tsutomu Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuhiko Hoshii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Nishiyama.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishiyama, T., Hoshii, T. Testosterone-guided ADT for prostate cancer. Nat Rev Urol 13, 189–191 (2016). https://doi.org/10.1038/nrurol.2016.9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.9

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research